Toggle Main Menu Toggle Search

Open Access padlockePrints

The Newcastle University research output collection, currently available on ePrints, will shortly be moving to a new open repository platform, Figshare. To prepare for the data migration we have paused adding new content to ePrints, and will resume once the new repository is launched. During this time you will continue to have access to ePrints (but no new content will appear). We will share updates here when available.

Platelet Monocyte Aggregates and Monocyte Chemoattractant Protein-1 are not Inhibited by Aspirin in Critical Limb Ischaemia

Lookup NU author(s): Dr Jonathan Smout, Professor Gerard StansbyORCiD

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

Objectives: Platelet monocyte aggregates (PMA) and monocyte chemoattractant protein-1 (MCP-1) play a significant role in atherosclerotic disease but the effect of aspirin and their role in peripheral arterial disease (PAD) requires further investigation. We have compared p-selectin, PMA and MCP-1 in patients with PAD treated with aspirin (75mgs daily), with age matched controls not treated with aspirin. Materials and methods: Using flow cytometry and ELISA, P-selectin, PMA and MCP-1 were compared in 3 populations; healthy controls (n = 12), intermittent claudication (n = 19) and critical limb ischaemia (CLI), (n = 10). Results: P-selectin was significantly higher in CLI patients (3.48% positive) compared to the claudicants (1. 36% positive) and the controls (1.76% positive). PMA levels were significantly higher for CLI population (44.5% positive) compared to the claudicants (20.48% positive) and the controls (28.33% positive). MCP-1 levels expression was significantly higher for the CLI patients (175.4 pg/mL) compared to the claudicants (76.1 pg/mL) and the controls (117.0 pg/mL). Conclusion: Despite aspirin treatment CLI patients have higher platelet activation and MCP-1 expression than controls and claudicants. With increasing severity of disease aspirin is unable to suppress markers of platelet activation and pro-atherosclerotic chemokine expression which may represent another form of aspirin resistance. © 2007 Elsevier Ltd. All rights reserved.

Publication metadata

Author(s): Cleanthis M, Bhattacharya V, Smout J, Ashour H, Stansby G

Publication type: Article

Publication status: Published

Journal: European Journal of Vascular and Endovascular Surgery

Year: 2007

Volume: 33

Issue: 6

Pages: 725-730

ISSN (print): 1078-5884

ISSN (electronic): 1532-2165

Publisher: Elsevier Ltd

URL: http://dx.doi.org/10.1016/j.ejvs.2006.12.025

DOI: 10.1016/j.ejvs.2006.12.025

PubMed id: 17296320

Altmetrics

Altmetrics provided by Altmetric

Share